# First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

> **NCT06070740** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Gastrointestinal Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Durvalumab and Chemotherapy(oxaliplatin and capecitabine)

## Key facts

- **NCT ID:** NCT06070740
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2023-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06070740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06070740, "First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06070740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*